Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

CRANBURY, N.J., Nov. 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2012. 

Recent Highlights
On July 3, 2012, Palatin closed on a private placement of 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of its common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of its common stock. Aggregate gross proceeds to Palatin were $35,000,000, with net proceeds, after deducting offering expenses, of $34,407,446.

On September 27, 2012, at a special meeting Palatin stockholders voted to increase its authorized common stock from 100,000,000 to 200,000,000 shares, and Palatin filed a certificate of amendment with the Secretary of State of Delaware the same day. This satisfied certain contractual obligations relating to the Series B 2012 warrants in its 2012 private placement, so that interest will not be payable on the value of the Series B 2012 warrants and Palatin will not be required to redeem the Series B 2012 warrants for failure to increase the number of authorized shares.

On November 8, 2012, Palatin reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, demonstrate that women taking bremelanotide showed clinically meaningful and statistically significant increases
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015 - Development of a ... the VOLVOX Platform - To be Presented on Tuesday, ...  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal ... Sunday, Apr 19, 1:00 PM EST Invictus ... today announced that the company,s novel computational platform technology ...
(Date:4/20/2015)... MIAMI (PRWEB) April 20, 2015 ... attend The Aesthetic Meeting 2015, an annual gathering of ... Alfredo Hoyos, M.D., is scheduled to introduce the company’s ... injection techniques with adipose-derived stem cell techniques. , ... that concern patients in the aesthetic field, including facial ...
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... - Conference Call to Discuss Results to Be Held at ... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 29, 2009 before the open of the U.S. financial markets.The ... at 9:00 a.m. Eastern Time on the same day. ...
... Human Tissue Collection and Specimen Management Provide FocusMEMPHIS, ... the physician partners of Accelerated Community Oncology Research ... (USA), has begun acquiring human tissue samples for ... World BioBank supports biomarker storage in conjunction with ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
Cached Biology Technology:ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... that freezing kidney tumors through percutaneous cryoablation shows promise ... Their early findings showing short-term success in more ... this month’s issue of Radiology. , The standard treatment ... of a long-term cure. For some patients, surgery ...
... Medicine has helped confirm the reliability of a new ... long-promised era of personalized medicine based on each individual's ... five sites that helped determine that the genetic test ... developing cirrhosis from chronic hepatitis C infection. That means ...
... A study of eight hospitals in Peru has shown ... double that of mechanically ventilated negative-pressure rooms and 18 ... , The researchers, led by Rod Escombe from ... ventilated clinical rooms such as respiratory isolation rooms, TB ...
Cached Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: